Recursion Pharmaceuticals
RXRX
RXRX
268 hedge funds and large institutions have $1.89B invested in Recursion Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 110 increasing their positions, 47 reducing their positions, and 46 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
11% less capital invested
Capital invested by funds: $2.12B → $1.89B (-$234M)
45% less call options, than puts
Call options by funds: $12.3M | Put options by funds: $22.3M
Holders
268
Holding in Top 10
6
Calls
$12.3M
Puts
$22.3M
Top Buyers
| 1 | +$115M | |
| 2 | +$41.6M | |
| 3 | +$37.4M | |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$26.7M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$18.9M |
Top Sellers
| 1 | -$12M | |
| 2 | -$10.5M | |
| 3 | -$9.19M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.01M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$6.59M |